Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Clin Cancer Res. 2023 May 1;29(9):1645-1647. doi: 10.1158/1078-0432.CCR-23-0048.
Immune checkpoint blockade has been ineffective in ovarian cancer, and there is an ongoing effort to identify biomarkers of therapeutic benefit. Despite promising preclinical data, a substudy of the IMagyn050 trial found that patients with homologous recombination deficient tumors did not have improved progression-free survival with the addition of the PD-L1 inhibitor atezolizumab. See related article by Landen et al., p. 1698.
免疫检查点阻断在卵巢癌中无效，目前正在努力寻找治疗获益的生物标志物。尽管有很有前景的临床前数据，但 IMagyn050 试验的一项亚研究发现，添加 PD-L1 抑制剂阿替利珠单抗并未改善同源重组缺陷肿瘤患者的无进展生存期。有关详情，参见 Landen 等人的文章第 1698 页。
